Delving into the Latest Updates on Acetaminophen with Synapse

Overview

Basic Info

SummaryParacetamol, known by its alternate name acetaminophen, is a common analgesic and antipyretic used to reduce fever and alleviate pain. Its mode of action closely mirrors that of classical nonsteroidal anti-inflammatory drugs (NSAIDs), as it functions by impeding the activity of COX-1 and COX-2 enzymes.Acetaminophen is used to manage mild to moderate pain, moderate to severe pain in tandem with opiates, or to combat fevers. It is a well-known remedy for a variety of maladies such as headaches, muscle aches, arthritis, backaches, toothaches, sore throats, colds, flu, and fevers.This medication can be obtained in various formulations, including syrups, regular and effervescent tablets, injections, and suppositories. Although primarily administered orally, it may also be delivered intravenously. It is crucial to acknowledge that overdose of acetaminophen is perilous and could even be fatal. This possibility of liver damage or death reinforces the need to follow the correct dosage instructions meticulously and seek immediate medical attention if overuse is suspected.Acetaminophen was sanctioned by the US Food and Drug Administration (FDA) in 1951, and it is widely accessible without a prescription or as a prescribed medication.

Drug Type

Small molecule drug

Synonyms

4'-hydroxyacetanilide, 4-(Acetylamino)phenol, 4-ACETAMIDOPHENOL

+ [90]

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

AnalgesiaFeverPain

Inactive Indication

Acute migraineAcute PainAnesthesia+ [24]

Originator Organization

Dandong Yichang Pharmaceutical Co., Ltd.

Active Organization

Fresenius Kabi USA LLC

Terumo Corp.Viatris Healthcare GK

+ [11]

Inactive Organization

Cosette Pharmaceuticals, Inc.

Taro Pharmaceutical Industries Ltd.

Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA

+ [21]

License Organization

Seelos Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1966),

FeverPain

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC8H9NO2

InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

CAS Registry103-90-2

The goal of this interventional study is to learn if an Enhanced Recovery After Surgery (ERAS) protocol works to reduce the need for narcotic pain medications in live donor kidney transplant recipients. The main questions it aims to answer are:
Does the ERAS protocol lower the amount of opioid narcotic medication needed to manage post-surgery pain? Does the ERAS protocol help lower pain scores after surgery? Researchers will compare the ERAS protocol to previous patients where the ERAS protocol was not used to see if the ERAS protocol works to reduce post-surgery pain.
Participants will be asked to:
* Drink a pre-surgery carbohydrate drink two hours before your surgery.
* Take a pre-surgery dose of Tylenol by mouth.
* Take a pre-surgery dose of Gabapentin by mouth.
* The surgeon will administer a local numbing medication at the surgery site by injection during the surgery.
* Begin walking with assistance about 12 hours after your surgery.
* Allow the research staff to collect data about your kidney function. This data will be collected on your postoperative clinic visits, which generally occur about twice weekly for one month. This information will determine your kidney health, need for hospitalization, and side effects that may occur.

Start Date15 Oct 2025

Sponsor / Collaborator

Baylor Research Institute

NCT07197684

/ Not yet recruitingNot ApplicableIIT

Effect of Ultrasound Guided Pecs Block With Intravenous Ketamine and Ketamine Infusion Alone For Prevention of Chronic Post-Surgical Pain in Patients Undergoing Breast Cancer Surgery: A Randomized Controlled Trial

The goal of this clinical trial is to is to compare the effectiveness of ultrasound-guided Pecs block with intravenous ketamine versus intravenous ketamine infusion alone in preventing Chronic Post-Surgical Pain (CPSP) in patients undergoing breast cancer surgery. The main question it aims to answer is,
How effective is the ketamine and ketamine with pecs block in reducing the frequency of Chronic Post-Surgical Pain after breast cancer surgery

Start Date06 Oct 2025

Sponsor / Collaborator

Aga Khan University

100 Clinical Results associated with Acetaminophen

Login to view more data

100 Translational Medicine associated with Acetaminophen

Login to view more data

100 Patents (Medical) associated with Acetaminophen

Login to view more data

49,541

Literatures (Medical) associated with Acetaminophen

01 Feb 2026·TISSUE & CELL

Ultrasonic irradiation for ZnO NPs Synthesis and their hepatoprotective effect against acetaminophen induced hepatic toxicity in albino rats: Biochemical, physiological, and histopathological assessments

Article

Author: Mahboub, Heba H ; Ismail, Sameh H ; Ezz-Eldin, Rasha M M ; Mansour, Yasmine A ; Youssef, Fady Sayed ; Hussein, Shaymaa ; Mohamed, Gehad G ; Ibrahim, Sherin ; Abdelfattah, Abdelfattah M ; AbdEl Halim, Hanan F

The present novel trial assesses the prophylactic influence of ZnO NPs in comparison to silymarin against liver damage induced by acetaminophen (APAP). Forty albino rats were allocated into 4 groups (n = `10 rats/ group). Group I (Control), was orally administered 0.9 % NaCl for 21 days. Group II (exposed to APAP) received distilled water (1 ml/kg per day) via oral gavage for 19 successive days followed by APAP (600 mg/kg, PO) twice daily for 2 days. Group III (APAP+ Silymarin) was orally administered silymarin at the dose of 200 mg/kg daily for 19 days followed by APAP (600 mg/kg) via oral gavage twice daily for 2 successive days. Group IV (APAP+ ZnO NPs) was orally given ZnO NPs at the dose of 100 mg/kg daily for 19 days followed by (600 mg/kg/ twice daily) APAP orally for 2 successive days. APAP exhibited a substantial elevation of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, nitric oxide and malondialdehyde levels. Meanwhile, APAP markedly decreased catalase, SOD, GST and TAC levels. A significant elevation in DNA damage inside hepatocytes was noticed. APAP induced many histopathological changes. Conversely, the prophylactic use of ZnO NPs inhibited the elevation of AST, ALT, ALP, NO and MDA as well as the decline of catalase, SOD, GST and TAC levels induced by APAP toxicity compared to group III. Marked improvement of the architecture of hepatic tissue was noticed in group IV. In conclusion, ZnO-NPs were more actual in ameliorating APAP hepatotoxicity compared to silymarin via antioxidant and antiapoptotic pathways.

01 Feb 2026·JOURNAL OF CRITICAL CARE

Evaluation of bromocriptine for the reduction of fever in patients with acute neurologic injury: A retrospective cohort study

Article

Author: Sieg, Emily ; Livers, Kristen ; Weitkamp, Lindsay ; Campbell, Michelle ; Rhodes, Mikaela ; Daniels, Michael W

BACKGROUND/OBJECTIVE:

Fever is prevalent among patients with neurologic injury and has traditionally been treated with antipyretics and surface cooling modalities. Dopamine (D2) receptor agonists, such as bromocriptine, have shown a benefit for the treatment of central fever; however, there are currently no guidelines for the use of bromocriptine in this population. The purpose of this study was to evaluate the safety and efficacy of bromocriptine plus acetaminophen compared to acetaminophen alone for the treatment of fever in patients with acute neurologic injury.

METHODS:

This was a retrospective cohort study of patients admitted to the neurosciences intensive care unit (Neuro ICU) with an acute neurologic injury who received bromocriptine 5 mg every 8 h plus acetaminophen (BROMO) or acetaminophen alone (APAP) for the indication of fever. The primary outcome was reduction of temperature (°C) 72 h after initiation of bromocriptine and acetaminophen or acetaminophen alone.

RESULTS:

A total of 67 patients were included; 28 patients were included in the BROMO group and 39 patients in the APAP group. There was a significant reduction in temperature at 72 h in the BROMO group compared to the APAP group (-0.86 °C vs -0.39 °C, p = 0.017). No adverse effects were noted in either group.

CONCLUSION:

This study found that bromocriptine 5 mg every 8 h is safe when used in combination with acetaminophen for fever management among patients with neurologic injury. Additional prospective, multi-center studies are needed to further elucidate the role of bromocriptine in the treatment of fever in the Neuro ICU.

01 Jan 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Investigation of dielectric studies of paracetamol-diethylamine solutions: Experimental and machine learning approach

Article

Author: Jain, Prince ; Rana, V A ; Prajapati, P M ; Pandit, T R ; Thakor, Sanketsinh

This paper discusses about the dielectric studies of binary mixtures of paracetamol (PCM) and Diethylamine (DEA). Parallel resistance (R_p) and Parallel capacitance (C_p) measured using a precision LCR meter over a frequency range of 20 Hz-2 MHz at four distinct temperatures, starting from 293.15 K and increasing by 10 K for each subsequent measurement. These experimental parameters were used to compute the complex dielectric function, from which electrical properties like complex conductivity, complex impedance and complex electrical modulus-were derived. In addition to conventional analysis, machine learning (ML) models were implemented to predict dielectric constant (ε') and dielectric loss (ε″) values based experimental inputs, with their predictive performance significantly enhanced through Bayesian hyperparameter optimization. This dual approach of combining experimental data with ML modelling offers a novel methodology for efficient and accurate characterization of dielectric systems. The added value of this study lies in its ability to bridge physical measurements with computational predictions, reducing experimental workloads and improving generalization in similar systems. The findings have potential applications in material science, pharmaceuticals, and electronic device modelling. This study demonstrates that ML assisted dielectric analysis can serve as a powerful tool in predictive material characterization.

624

News (Medical) associated with Acetaminophen

24 Oct 2025

·www.einpresswire.com

Pregnancy, medicine and inequality: why we must do better

Dr Lucy Mackillop FRCP, consultant obstetric physician, reflects on the inequalities experienced during pregnancy in medical research, mortality and healthcare. Pregnancy is a time of profound physiological change, yet women and people who are pregnant or breastfeeding remain one of the most underrepresented groups in medical research. This exclusion has led to gaps in evidence, fragmented health policies and inequitable outcomes, especially for those from marginalised communities. Despite the widespread use of medications during pregnancy (over 80% of pregnant women and pregnant people take prescription drugs, excluding vitamins), most medicines have not been adequately tested for safety or efficacy in this population. The result? Pregnant women and pregnant people are often advised to stop taking necessary medications due to unknown fetal risks, while the risks to their own health go unmeasured and unaddressed. The fetal risks associated with maternal disease are sometimes not fully recognised, and undertreatment during pregnancy can lead to adverse fetal outcomes such as pre-term birth or growth restriction. The recent claim by the US administration is an example of this. Pregnant women and pregnant people were warned against taking paracetamol because of unproven links between the drug and autism spectrum disorders in children, yet we know that untreated fever and pain during pregnancy carry risks that must not be overlooked. There is no evidence that taking paracetamol during pregnancy causes autism in children , and paracetamol is still recommended as the first-choice pain reliever during pregnancy. The misinformation from the US administration – an authoritative source – concerns me, as does the lack of safety evidence for most drugs in pregnancy. A global analysis by the WHO’s Global Observatory on Health Research and Development revealed that only 4% of clinical trials over the past decade included pregnant women. As a result, many are left without treatment options or take prescription medicines off-label, without robust data to guide safe use. This isn’t just a scientific oversight; it’s a human rights issue. Pregnant women and pregnant people deserve the same access to effective, evidence-based treatments as anyone else. Yet the lack of inclusion in trials means they are routinely denied that right. Maternal mortality and inequality Inequality is also visible in maternal mortality statistics. According to MBRRACE-UK data published on 11 September 2025, maternal deaths in the UK have steadily increased since 2012. Two-thirds of those who died had an underlying medical condition (excluding obesity), and most died from non-obstetric causes, conditions that could potentially be managed with appropriate medical care. But the data also reveal stark inequalities: Black people face more than double the risk of maternal death compared to White people Pregnant women in the most deprived areas of England have nearly twice the mortality rate compared to those in the least deprived areas. These disparities are multifactorial, rooted in social determinants, systemic bias and unequal access to care. But they must be acknowledged and addressed across all areas of medicine, including the physician community, and not just obstetrics and gynaecology, as most pregnant women and pregnant people who die in the UK die of a non-obstetric cause. To improve outcomes, we must include women and people who are pregnant or breastfeeding in clinical trials and ensure representation across diverse demographic groups. Encouragingly, the European Medicines Agency is preparing to publish guidelines on the inclusion of pregnant and breastfeeding individuals in clinical trials, a long-overdue step toward equity. But inclusion alone isn’t enough. We also need: real-world evidence from pharmacovigilance registries balanced risk-benefit analyses in prescribing decisions greater awareness among all healthcare professionals, not just obstetricians. Pregnant women and pregnant people deserve treatments that are not only safe for their babies but also protective of their own health. That means moving beyond a focus on embryo or fetotoxicity in treatment decisions to recognising the full spectrum of risks and needs. The lack of research, the rise in maternal deaths, and the persistent inequalities in outcomes all point to one truth: we are failing pregnant women and pregnant people, especially those from marginalised communities. Improving maternal health isn’t just about better science. It’s about equity, inclusion and respect. And it starts with recognising that pregnant women and pregnant people have the same right to safe, effective healthcare as anyone else. Dr Lucy Mackillop is chair of the Joint Committee for Obstetric Medicine and president of the MacDonald Obstetric Medicine Society, as well as a fellow of the Royal College of Obstetricians & Gynaecologists. Are you a resident doctor interested in obstetric medicine? The RCP credential in obstetric medicine, which leads to a Professional Diploma in Obstetric Medicine, has been designed for resident doctors in the UK with an interest in this specialist area. Applications for 2026 will open later this year. Find out more . Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

23 Oct 2025

·pharma.economictimes.indiatimes.com

CDSCO flags 112 substandard drug samples in September; one cough syrup marked as spurious

New Delhi: Under its monthly quality review drive, the Central Drugs Standard Control Organization ( CDSCO ) has identified 112 Not of Standard Quality (NSQ) drug samples along with a spurious sample of a cough syrup. Making the announcement, the Union Health Ministry in a note sated that, of the total 112 NSQ samples, Central Drugs Laboratories have identified 52, while the remaining 60 were flagged by State Drugs Testing Laboratories. The NSQ list of September includes several common medicines such as Paracetamol, Pantoprazole,, Multivitamin supplements and several other common drugs. Meanwhile, as per the CDSCO alert the drug sample flagged as spurious by the state drug testing laboratory in Chhattisgarh is of a dry cough syrup ‘Besto-Cof’ Several e-pharmacy platforms have listed the drug as a formulation of Phenylephrine, Chlorpheniramine Maleate and Dextromethorphan Hydrobromide marketed by ‘ BestoChem Formulations India Ltd. ’ “The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and the same is a spurious drug.” the alert, suggests. According to CDSCO, the product is purported to be spurious, subject to outcome of an ongoing investigation into the matter. Under the Drugs and Cosmetic act of 1940, a drug is deemed as spurious if it is manufactured under a name which belongs to another drug and resembles in a manner likely to deceive consumers. The identification of a spurious cough syrup from the batches collected in September coincides with a tragic incident in Madhya Pradesh (an adjoining state to Chhattisgarh) where at least 24 children died after consuming a cough syrup brand Coldrif., later found found to contain 48.6 per cent Diethylene Glycol (DEG), a toxic solvent whose permissible limit in pharmacopeial formulations is only 0.1 percent. In October, two more brands—Respifresh TR and ReLife—were identified as contaminated with Diethylene Glycol (DEG) beyond the permissible limit; however, they were not linked to any of the reported casualties in MP. Following a official communication from the CDSCO, last week the World Health Organisation (WHO) had issued a global alert for three brands–Coldrif manufactured by Tamil Nadu-based Sresan Pharmaceuticals, Respifresh TR by Gujarat-based Rednex Pharmaceuticals and ReLife by Shape Pharma. Accordion to a PTI report the Union Health Ministry is also mulling to bring a new law replacing the Drugs and Cosmetics act of 1940 to arm the central body with more powers such as, “to take immediate action against manufacturers of fake or substandard medicines.” Meanwhile, the central regulator on its part has also undertaken several measures including mandatory testing of raw material used for producing formulations, online monitoring of high risk solvents along with conducting risk-based inspections at serval pharma clusters. By Online Bureau ,

21 Oct 2025

·www.fiercepharma.com

Kenvue calls on FDA to reject proposed Tylenol safety warnings, pushes back on alleged autism link

Kenvue listed dozens of scientific rebuttals to the notion that Tylenol can be linked to an increased risk of autism and other neurodevelopmental disorders if used during pregnancy. After popular pain med Tylenol came under fire from officials in the Trump administration for an alleged link to autism if used during pregnancy, the product's manufacturer is fighting back at a proposed FDA label change by laying out evidence in support of the product's safety.The 42-page submission (PDF) from Kenvue was filed on Oct. 17 as a comment to an FDA Citizen Petition that the Informed Consent Action Network (ICAN) submitted to the agency on Sept. 23. The petition calls on the FDA to revise its label for all over-the-counter (OTC) drugs containing acetaminophen, Tylenol’s active ingredient, to include warnings against their use during pregnancy.ICAN's 12-page petition requests that the agency change the drug's label to note that “studies show that frequent use of this product during pregnancy may increase your child’s risk of neurodevelopmental disorders” and that pregnant women should, if “strictly necessary,” use the “lowest effective dose for the shortest possible time” to treat pain or fever. Kenvue has repeatedly backed the safety of its product and now has taken the chance to directly respond to ICAN’s arguments. ICAN is a litigious activist organization that’s dedicated to the “eradication of man-made disease," according to its website.Along with sharing the findings of 50 years' worth of research on the med, Kenvue pointed to the FDA’s own long-held position on the use of acetaminophen during pregnancy, suggesting that a label change would mark an “unexplained departure” from the agency’s stance. As recently as August, the FDA’s acetaminophen-specific web page listed that it had “not found clear evidence” that appropriate use of the drug causes adverse developmental outcomes.Kenvue also reminded the FDA of its own repeated cautions about the “potential dangers of overwarning,” explaining that the agency has “consistently emphasized” that OTC warnings must be “clear, concise, and evidence-based” so as to not confuse consumers or weaken key safety messages.“Because the science does not support a change to the warning language and the proposed labeling changes could be harmful to pregnant women and result in adverse pregnancy outcomes, Kenvue strongly opposes the changes and believes that the existing instruction to speak to a health professional before use in pregnancy is the most conservative and appropriate labeling,” the company wrote in its response. As Kenvue advises, any agency action other than denying the petition would be “arbitrary and capricious” and could violate federal law that dictates the administrative process of label changes. Tylenol has long been marketed by Johnson & Johnson since its first approval many decades ago, but the franchise recently switched hands to the company’s consumer healthcare spinout Kenvue. The drug is “one of the most studied medicines in history,” according to Kenvue, with more than 150 studies supporting its safety and efficacy profile. White House autism push U.S. health officials began floating a potential link between autism and Tylenol use in September, months into Department of Health and Human Services Secretary Robert F. Kennedy Jr.’s investigation into the nation's “autism epidemic.” At a White House press conference, President Donald Trump advised that pregnant women should “tough it out” and not take Tylenol, citing a “very increased” risk of autism. That day, FDA Commissioner Marty Makary, M.D., inked a notice to physicians urging them to “consider minimizing” the use of acetaminophen during pregnancy to treat “routine low-grade fevers.”However, Makary’s letter clarified that a causal relationship between acetaminophen use during pregnancy and autism has not been established. Still, the agency announced on Sept. 22 that it had “initiated the process” for a label change.

Drug Approval

100 Deals associated with Acetaminophen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00217	Acetaminophen	N02BE01	DB00316

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Headache	United States	Cosette Pharmaceuticals, Inc.	09 Feb 1978
Analgesia	Japan	Iwaki Seiyaku Co., Ltd.	01 Jul 1966
Fever	China	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966
Pain	China	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Toothache	Phase 3	United States	Johnson & Johnson Holdco (NA), Inc.	19 Jul 2017
Common Cold	Phase 3	-	GSK Plc	01 Feb 2017
Pharyngitis	Phase 3	-	GSK Plc	01 Feb 2017
Episodic tension-type headache	Phase 3	United States	GSK Plc	01 Apr 2013
Acute Pain	Phase 3	United States	Mallinckrodt Plc	01 Jan 2008
Pain, Postoperative	Phase 3	United States	Mallinckrodt Plc	01 Nov 2006
Uterine Neoplasms	Phase 3	United States	Mallinckrodt Plc	01 Nov 2006
Acute migraine	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Mar 2006
Osteoarthritis, Hip	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	18 Oct 2005
Diabetic Neuropathies	Phase 3	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06019728 (SHORTEN, CTgov)	Phase 4	Fabry Disease	8	Fabrazyme	onsikrcdnh(mkmgaiyuhz) = zbijtwiohx mknpfgkhqb (xqsxtpgkbc, iggzprlqch - lyexzfytqy) View more	-	21 Oct 2025
NCT03365622 (CTgov)	Phase 4	-	214	Placebo Oral Tablet+acetaminophen (IV Acetaminophen and Placebo Pills)	cjlrzylzdv(enmaswcxpz) = tynzrhfyet lsqesavpmu (mveyoixrij, 58.16) View more	-	29 Jun 2025
				Placebos+Acetaminophen (Placebo IV (Normal Saline) + Oral Acetaminophen)	cjlrzylzdv(enmaswcxpz) = tfibdycmsv lsqesavpmu (mveyoixrij, 57.59) View more
NCT02356159 (CTgov)	Phase 1/2	Hodgkin's Lymphoma \| Multiple Myeloma \| acute leukemia ... View more	34	Epinephrine+PET+Acetaminophen+prednisone+EPOCH-F+Palifermin+Diphenhydramine+Rituximab (2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose)	wemkykhahr = gyqhgvafai ptwauhmmfr (brzodcyvgi, gjmqccklmv - fjiwaphykn)	-	05 Jun 2025
				Epinephrine+PET+Acetaminophen+prednisone+EPOCH-F+Palifermin+Diphenhydramine+Rituximab (1/Phase 1: Dose Escalation Arm - Palifermin)	zqkbedxrcs = pqeygemteb wpbdknxuex (kqlfgseaqx, gqxggqwzax - ririuxkvww)
NCT04574778 (Pubmed \| Reg Anesth Pain Med) Manual	Phase 3	Pain, Postoperative	82	Intravenous acetaminophen	batzrzzmvz(gshpoczbub) = svdnqfqpsr olahzutovg (mkcfoqghdf, 4.0 - 27.1)	Negative	01 Jun 2025
				Oral acetaminophen	batzrzzmvz(gshpoczbub) = bnffmieujf olahzutovg (mkcfoqghdf, 4.0 - 29.5)
ATS2025	Not Applicable	Sepsis baseline plasma IL-8 \| sTNFR1 \| serum bicarbonate ... View more	447	Acetaminophen (Hyperinflammatory Phenotype)	iuxhrmpjdc(fppcvtmfux) = snysizuzsx wovitxldlz (eklznsrmpi ) View more	Negative	16 May 2025
				Acetaminophen (Hypoinflammatory Phenotype)	iuxhrmpjdc(fppcvtmfux) = lrtnqcowiz wovitxldlz (eklznsrmpi ) View more
NCT00585559 (CTgov)	Phase 3	Aneurysm, Intracranial Berry, 1 \| Vasospasm, Intracranial	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	ttztwgleob(jubtwmlnwd) = vckscsibzt rjlpruzulz (lonyckmpqx, uantthobxv - qdaqdyyncb) View more	-	18 Apr 2025
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	ttztwgleob(jubtwmlnwd) = nketwglrgf rjlpruzulz (lonyckmpqx, qszixfxypf - xllcskfuck) View more
NCT06514222 (Pubmed \| Sci Rep)	Early Phase 1	Pain	56	Ibuprofen 400 mg + Paracetamol 500 mg every 8 h	crzhjucmum(gxvuvimubw) = tkkkttsjxt elyxwkzipb (ptxdxdjrig ) View more	Positive	03 Apr 2025
				Ibuprofen 400 mg + Paracetamol 500 mg alternatively every 4 h	crzhjucmum(gxvuvimubw) = xopepnmrmt elyxwkzipb (ptxdxdjrig ) View more
NCT05647681 (Pubmed \| Pain Med)	Phase 1	Soft Tissue Injuries	-	Paracetamol	wgvpwhvavu(tjuwsevdlt) = eewiclgltj qvwkhykzfw (nfubiwzkjm ) View more	Positive	05 Mar 2025
NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	kltecdwiph(ocpkimwjem) = lkbwhsooti ptaqlwnrcm (ccfcnutcgl, esnszxplln - thapkcbnem) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	kltecdwiph(ocpkimwjem) = cgedgbkokw ptaqlwnrcm (ccfcnutcgl, npdjafktsg - ruqzlgmkuq) View more
NCT06601114 (Pubmed \| Mol Cell Pediatr)	Not Applicable	Ductus Arteriosus, Patent	256	Paracetamol	kijjvfliuu(yadjkbnfds) = csxpgewmih jjbuamqbcl (ozgvxcqdre )	Positive	25 Jan 2025
				Ibuprofen	kijjvfliuu(yadjkbnfds) = cxdunvjlej jjbuamqbcl (ozgvxcqdre )